INBP on OTC
INTEGRATED BIOPHARMA INC
American pharmaceutical preparations company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Xilio Therapeutics, Inc., CUMBERLAND PHARMACEUTICALS INC or Aquestive Therapeutics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
1.8%Gross margin2
-6.2%Operating margin2
-6.5%Net margin2
-19.3%Revenue growth, 20262
-16.1%Return on equity2
$895.0KFree cash flow2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Business segments
Contract Manufacturing brought in 97% of the revenue INTEGRATED BIOPHARMA INC broke down this way in fiscal 2026.
Business segments by year
| Business segments | 2025 | 2026 |
|---|---|---|
| Contract Manufacturing | $51.7M | $42.4M |
| Other Nutraceutical Business | $2.7M | $1.5M |
Regions
United States brought in 80% of the revenue INTEGRATED BIOPHARMA INC broke down this way in fiscal 2026.
Regions by year
| Regions | 2025 | 2026 |
|---|---|---|
| United States | $43.6M | $35.2M |
| Outside the United States | $10.7M | $8.6M |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue92¢$43.1M
- Selling, general and admin7¢$3.5M
- Interest0¢$12.0K
- Income tax1¢$279.0K
Out of $43.9M in revenue.2 The company lost money this year.
Where each dollar of operating cash went, fiscal 2026
- Capital spending28¢$346.0K
- Kept or used elsewhere72¢$895.0K
Out of $1.2M of cash from operations.2
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Sales, net | $43.9M | $54.4M |
| Cost of sales | $43.1M | $48.8M |
| Gross profit | $800.0K | $5.6M |
| Selling and administrative expenses | $3.5M | $3.5M |
| Operating (loss) income | -$2.7M | $2.0M |
| Interest income, net | $154.0K | $39.0K |
| Other income (expense), net | -$12.0K | $3.0K |
| Total other income, net | $142.0K | $42.0K |
| (Loss) income before income taxes | -$2.6M | $2.1M |
| Income tax expense, net | $279.0K | $1.3M |
| Net (loss) income | -$2.8M | $808.0K |
| Basic net (loss) income per common share (in dollars per share) | -$0.09 | $0.03 |
| Diluted net (loss) income per common share (in dollars per share) | -$0.09 | $0.03 |
| Weighted average common shares outstanding - basic (in shares) | 31.1M shares | 30.3M shares |
| Add: Equivalent shares outstanding - stock options (in shares) | 0 shares | 872.7K shares |
| Weighted average common shares outstanding - diluted (in shares) | 31.1M shares | 31.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash | $4.5M | $3.6M | ||
| Accounts receivable (less allowance of credit losses of $20) | $3.3M | $5.4M | ||
| Inventories | $9.1M | $9.4M | ||
| Other current assets | $432.0K | $356.0K | ||
| Total current assets | $17.4M | $18.8M | ||
| Property and equipment, net | $1.8M | $1.7M | ||
| Finance lease right-of-use assets | $144.0K | $144.0K | $171.0K | |
| Deferred tax assets, net | $3.1M | $3.3M | ||
| Security deposits and other assets | $53.0K | $52.0K | ||
| Total Assets | $25.3M | $24.9M | ||
| Accounts payable | $3.2M | $2.3M | ||
| Accrued expenses and other current liabilities | $1.4M | $1.3M | ||
| Current portion of finance lease obligation | $48.0K | $48.0K | $45.0K | |
| Total current liabilities | $5.8M | $4.2M | ||
| Finance lease obligations | $67.0K | $67.0K | $115.0K | |
| Operating lease obligations | $1.8M | $221.0K | ||
| Total Liabilities | $7.7M | $4.6M | ||
| Common Stock, $0.002 par value; 50,000,000 shares authorized; 31,094,510 and 31,059,610 shares issued and outstanding, respectively | $62.0K | $62.0K | ||
| Additional paid-in-capital | $52.0M | $51.8M | ||
| Accumulated deficit | -$34.3M | -$31.4M | ||
| Less: Treasury stock, at cost, 34,900 shares | -$99.0K | -$99.0K | ||
| Total Stockholders' Equity | $17.7M | $20.3M | $19.2M | |
| Total Liabilities and Stockholders' Equity | $25.3M | $24.9M | ||
| Allowance for credit losses | $20.0K | $20.0K | ||
| Operating lease right-of-use assets | $2.9M | $855.0K | ||
| Current portion of operating lease liabilities | $1.2M | $634.0K | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, outstanding (in shares) | 31.1M shares | 31.1M shares | ||
| Common stock, issued (in shares) | 31.1M shares | 31.1M shares | ||
| Treasury stock, shares (in shares) | 34.9K shares | 34.9K shares |
| Period ending | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2024-06-30 |
|---|---|---|---|---|
| Cash | $4.5M | $3.6M | ||
| Accounts receivable (less allowance of credit losses of $20) | $3.3M | $5.4M | ||
| Inventories | $9.1M | $9.4M | ||
| Other current assets | $432.0K | $356.0K | ||
| Total current assets | $17.4M | $18.8M | ||
| Property and equipment, net | $1.8M | $1.7M | ||
| Finance lease right-of-use assets | $144.0K | $144.0K | $171.0K | |
| Deferred tax assets, net | $3.1M | $3.3M | ||
| Security deposits and other assets | $53.0K | $52.0K | ||
| Total Assets | $25.3M | $24.9M | ||
| Accounts payable | $3.2M | $2.3M | ||
| Accrued expenses and other current liabilities | $1.4M | $1.3M | ||
| Current portion of finance lease obligation | $48.0K | $48.0K | $45.0K | |
| Total current liabilities | $5.8M | $4.2M | ||
| Finance lease obligations | $67.0K | $67.0K | $115.0K | |
| Operating lease obligations | $1.8M | $221.0K | ||
| Total Liabilities | $7.7M | $4.6M | ||
| Common Stock, $0.002 par value; 50,000,000 shares authorized; 31,094,510 and 31,059,610 shares issued and outstanding, respectively | $62.0K | $62.0K | ||
| Additional paid-in-capital | $52.0M | $51.8M | ||
| Accumulated deficit | -$34.3M | -$31.4M | ||
| Less: Treasury stock, at cost, 34,900 shares | -$99.0K | -$99.0K | ||
| Total Stockholders' Equity | $17.7M | $20.3M | $19.2M | |
| Total Liabilities and Stockholders' Equity | $25.3M | $24.9M | ||
| Allowance for credit losses | $20.0K | $20.0K | ||
| Operating lease right-of-use assets | $2.9M | $855.0K | ||
| Current portion of operating lease liabilities | $1.2M | $634.0K | ||
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, authorized (in shares) | 50.0M shares | 50.0M shares | ||
| Common stock, outstanding (in shares) | 31.1M shares | 31.1M shares | ||
| Common stock, issued (in shares) | 31.1M shares | 31.1M shares | ||
| Treasury stock, shares (in shares) | 34.9K shares | 34.9K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.2
| Period ending | 2026-06-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -$2.8M | $808.0K |
| Amortization of right-of-use assets | $1.1M | $951.0K |
| Depreciation and amortization | $293.0K | $318.0K |
| Deferred income taxes, net | $258.0K | $1.3M |
| Compensation expense on employee stock options | $192.0K | $185.0K |
| Allowance for (charge offs of) uncollectible accounts receivable, net | $0 | $19.0K |
| Loss on disposal of fixed assets | -$6.0K | $4.0K |
| Impairment charge on equipment | $30.0K | $28.0K |
| Other, net | $12.0K | -$10.0K |
| Accounts receivable | $2.1M | -$781.0K |
| Inventories | $220.0K | $1.9M |
| Other assets | -$89.0K | -$92.0K |
| Operating lease obligations | -$1.0M | -$945.0K |
| Accounts payable | $925.0K | -$211.0K |
| Accrued expenses and other current liabilities | $91.0K | -$1.4M |
| Net cash provided by operating activities | $1.2M | $2.1M |
| Purchase of property and equipment | -$346.0K | -$191.0K |
| Purchase portion of right of use asset - financed | $0 | -$14.0K |
| Proceeds from sale of property and equipment | $6.0K | $0 |
| Net cash used in investing activities | -$340.0K | -$205.0K |
| Proceeds from exercises of stock options | $0 | $86.0K |
| Repayments under financed lease obligations | -$45.0K | -$8.0K |
| Net cash (used in) provided by financing activities | -$45.0K | $78.0K |
| Net increase in cash | $856.0K | $1.9M |
| Interest | $9.0K | $47.0K |
| New Jersey state income taxes, net | $0 | $82.0K |
| Acquisition of operating right-of-use asset, net and operating lease obligations, net | $3.1M | $9.0K |
| Amount owed on purchase of property and equipment | $8.0K | $0 |
| Acquisition of finance right-of-use asset, net and finance lease obligations, net | $0 | $161.0K |
| Transfer of finance right-of-use asset, net to property and equipment, net | $0 | $80.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led INTEGRATED BIOPHARMA INC, and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2010201520202025
- Chief executive officerChristina Kay May 29, 2019 to now12
- Chief executive officerKay Riva May 29, 2019 to now13
- Chief executive officerJeffrey R. Leach Nov 17, 2008 to Nov 17, 200814
- Chief executive officerE. Gerald Kay Dec 4, 2006 to Dec 19, 201815
- ChairE. Gerald Kay May 29, 2019 to Nov 16, 202316
- PresidentE. Gerald Kay Oct 28, 2009 to Nov 16, 202317
- PresidentJeffrey R. Leach Nov 17, 2008 to Nov 17, 200814
- PresidentChristina Kay Dec 4, 2006 to Dec 4, 200618
- Chief financial officerDina Masi Sep 18, 2006 to now19
Board members and other officers (17)
- Vice PresidentChristina Kay Feb 15, 2007 to Dec 19, 201820
- Sr VP Admin. and OperationsEric J. Friedman Apr 17, 2006 to Apr 17, 200621
- Vice PresidentKay Riva Dec 4, 2006 to Dec 19, 201822
- Board memberDamon Desantis Jun 21, 2022 to now23
- Board memberEric J. Friedman Nov 17, 2020 to now24
- Board memberJoseph Laplaca Jun 9, 2015 to Nov 22, 201625
- Board memberGlenn Chang Aug 14, 2008 to Aug 14, 200826
- Board memberVidadi Yusibov Aug 14, 2008 to Aug 14, 200827
- Board memberJeffrey R. Leach Nov 17, 2008 to Nov 17, 200814
- Board memberBradley J. Hoecker Dec 29, 2008 to Dec 29, 200828
- Board memberWilliam H. Milmoe Dec 29, 2008 to now29
- Board memberCarl Desantis Feb 23, 2007 to Nov 4, 202130
- Board memberChristina Kay Dec 4, 2006 to now18
- Board memberE. Gerald Kay Dec 4, 2006 to Dec 19, 201815
- Board memberKay Riva Dec 4, 2006 to now22
- Board memberRobert Canarick Dec 4, 2006 to now31
- Board memberRobert Kay Dec 14, 2006 to Aug 14, 200832
Former names
Timeline
Filings
134 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 38 major events, 67 insider forms, 4 large holders, 5 other. The latest 20:
- Sep 25, 20268-K EDGAR
- Sep 25, 202610-K EDGAR
- Aug 20, 20268-K EDGAR
- Jul 2, 20268-K FORM 8-K PNC FIRST AMENDMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- Jun 25, 20264/A PRIMARY DOCUMENT EDGAR
- Jun 25, 20264 PRIMARY DOCUMENT EDGAR
- May 8, 20268-K EDGAR
- May 8, 202610-Q EDGAR
- Apr 17, 20264/A PRIMARY DOCUMENT EDGAR
- Apr 17, 20264 PRIMARY DOCUMENT EDGAR
- Apr 17, 2026SCHEDULE 13D EDGAR
- Apr 17, 20264 PRIMARY DOCUMENT EDGAR
- Apr 17, 2026SCHEDULE 13D/A EDGAR
- Apr 17, 20264 PRIMARY DOCUMENT EDGAR
- Apr 15, 20268-K EDGAR
- Mar 26, 20264 PRIMARY DOCUMENT EDGAR
- Mar 25, 20264 PRIMARY DOCUMENT EDGAR
The 134 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Carl DesantisSCHEDULE 13D/A, 1 filing Apr 17, 202633
- Damon DesantisSCHEDULE 13D, 1 filing Apr 17, 202634
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARKay Riva, Chief executive officer
- 14
- 15
- 16SEC EDGARE. Gerald Kay, Chair
- 17SEC EDGARE. Gerald Kay, President
- 18SEC EDGARChristina Kay, President
- 19SEC EDGARDina Masi, Chief financial officer
- 20SEC EDGARChristina Kay, Vice President
- 21
- 22SEC EDGARKay Riva, Vice President
- 23SEC EDGARDamon Desantis, Board member
- 24SEC EDGAREric J. Friedman, Board member
- 25SEC EDGARJoseph Laplaca, Board member
- 26SEC EDGARGlenn Chang, Board member
- 27SEC EDGARVidadi Yusibov, Board member
- 28SEC EDGARBradley J. Hoecker, Board member
- 29SEC EDGARWilliam H. Milmoe, Board member
- 30SEC EDGARCarl Desantis, Board member
- 31SEC EDGARRobert Canarick, Board member
- 32SEC EDGARRobert Kay, Board member
- 33
- 34